Back

First real world experience with the novel lipid-lowering drug PCSK9 inhibitor evolocumab in patients undergoing lipid apheresis: 1-year follow up

19 April 2018 (15:30 - 16:30)
Organised by:
Congress Presentation Part of: Moderated Poster Session II Lipids EAPC Premium Access EuroPrevent 2018

About the speaker

Photo
Mr Madan Raj Poudel

University Clinic OWL, Bielefeld (Germany)

9 More presentations in this session

Presentation thumbnail
Trimetazidine in the management of primary microvascular angina
Associate Professor I. Leonova (Saint Petersburg, RU)
Abstract
Presentation thumbnail
Prediction of subtle left ventricular systolic dysfunction in homozygous and heterozygous familial hypercholesterolemia: genetic analyses and speckle tracking echocardiography study
Doctor E. Saracoglu (Kocaeli, TR)
Presentation thumbnail
Exercise-induced changes in LDL and HDL levels are correlated with the exercise-induced CRP response- NEEDED 2014
Doctor C. Erevik (Stavanger, NO)
Abstract Slides
Presentation thumbnail
Differences in risk factors for three types of stroke: UK prospective study and meta-analyses.
Doctor L. Wright (Oxford, GB)
Abstract Slides
Presentation thumbnail
Comparative analyses of trends in hospitalisations for coronary heart disease subgroups in England and Australia
Doctor L. Nedkoff (Perth, AU)
Abstract Slides

Access the full session

Session thumbnail
Moderated Poster Session II

The Event

Event poster

EuroPrevent 2018

19 April 2018 15:30 CET
You may be interested in
thumbnail
Webinar
Unmet needs in lipid management: treatment goals and how to achieve them
thumbnail
Webinar
Risk assessment and lipid management in primary prevention
thumbnail
Congress Presentation
State-of-the-art lecture on how to keep your arteries young by tackling dyslipidaemia

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources